UNITED THERAPEUTICS CORP

United Therapeutics’ recent Form 4 shows a strategic option exercise, trust‑based tax planning, and concentrated voting power—insights for investors and regulators.

United Therapeutics (UTHR) shares surge to 33.5% ownership after a 9,500‑option exercise and multi‑day sales—see the SEC 10(b)(5) filing that details the strategy and impact.

United Therapeutics insider trading: CEO Martine A. Rothblatt’s trust‑based trades show disciplined equity management, hinting at future pipeline milestones and investor confidence.

United Therapeutics’ July 29 Form 4 shows CEO trades within SEC‑approved windows while the company advances inhaled prostacyclin, CRISPR‑AAV PAP, and a lung‑cancer immunotherapy combo.

United Therapeutics insider trades: Martine Rothblatt’s 10(b)(5) buys and sells show confidence in the firm’s pipeline and strategic liquidity management while keeping ownership stable.

United Therapeutics Corp. reports July 2026 executive share trades—CEO’s 330k‑share trust purchase confirms leadership confidence and regulatory transparency.

Rothblatt Martine A. exercised 9,500 UTHR options and sold 13,200 shares at $528–$540, leaving a 330k‑share holding—insider insight into United Therapeutics’ governance and market‑impact strategy.

United Therapeutics’ July 13 filings show director RSU vesting boosting insider stakes while S‑8 amendments keep compensation plans SEC‑compliant and transparent.

Explore how United Therapeutics’ CEO Martine Rothblatt’s $110M insider sales reflect strategic equity management, market timing, and investor sentiment in the rare‑disease sector.

United Therapeutics’ 2026 Form 8‑K reveals structured insider trades and option exercises, showing how senior leaders manage equity while staying fully compliant.